The latest Investing Matters Podcast episode with Inclusive Asset Management's Alexandra McGuigan has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 8.50
Ask: 9.50
Change: 0.00 (0.00%)
Spread: 1.00 (11.765%)
Open: 9.00
High: 9.00
Low: 9.00
Prev. Close: 9.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

2 Mar 2020 11:45

RNS Number : 6762E
Cantor Fitzgerald Europe
02 March 2020
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cantor Fitzgerald Europe

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Redx Pharma plc

(d) Date dealing undertaken:

28th February 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

REDX ORD 1P

Purchases

50,000

7.5 GBX

7.5 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Nil

Nil

Nil

Nil

Nil

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Nil

Nil

Nil

Nil

Nil

Nil

Nil

Nil

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Nil

Nil

Nil

Nil

Nil

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Nil

Nil

Nil

Nil

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

02nd March 2020

Contact name:

Andy Voong

Telephone number:

0207 894 7798

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFZGGFGZKGGZM
Date   Source Headline
12th Apr 20247:00 amRNSShare Purchase by a Director
10th Apr 20247:00 amRNSUpdate on Broking Arrangements
8th Apr 20243:32 pmRNSTR-1: Notification of major holdings
2nd Apr 20247:00 amRNSProposed Cancellation of Admission to Trading
14th Mar 202411:27 amRNSResult of AGM
6th Mar 20247:00 amRNSRedx to Exhibit Three Posters at AACR
28th Feb 20247:00 amRNSFirst Participant Dosed in Phase 1 Trial of RXC008
26th Feb 20247:00 amRNSRedx to Present at Cowen Health Care Conference
23rd Feb 20247:00 amRNSNew Grant of Options
16th Feb 20244:50 pmRNSNotice of AGM
14th Feb 20247:00 amRNSStatement re Press Report
8th Feb 20241:02 pmRNSTR-1: Notification of major holdings
7th Feb 20247:00 amRNSRedx announces sale of KRAS inhibitor program
15th Dec 20237:00 amRNSFinal Audited Results for Year Ended 30 September
12th Dec 20237:00 amRNSNotice of Preliminary Results
9th Nov 20237:00 amRNSHoldings in Company
8th Nov 20231:58 pmRNSTR-1: Notification of major holdings
8th Nov 20231:55 pmRNSTR-1: Notification of major holdings
7th Nov 20238:10 amRNSAdmission of Subscription Shares and TVR
6th Nov 202311:22 amRNSResults of General Meeting
6th Nov 20237:00 amRNSRedx Unveils Preclinical Data from RXC009
30th Oct 20237:00 amRNSRedx to present preclinical data on RXC009 at ASN
18th Oct 20237:00 amRNSProposed Subscription to raise c.£14.1 million
22nd Aug 20237:00 amRNSDirectorate Change
21st Aug 20237:00 amRNSZelasudil granted FDA Orphan Drug Designation
10th Jul 20237:00 amRNSExtension to Termination of Convertible Loan Notes
3rd Jul 20237:00 amRNSDirectorate Change
30th Jun 20237:00 amRNSNew Grant of Options
31st May 20237:00 amRNSRedx to present at Jefferies Healthcare Conference
17th May 20237:00 amRNSInterim Results for the Six Months Ended 31 March
12th May 20239:51 amRNSDiscovery of Pirtobrutinib Recognised with Plaque
11th May 20237:00 amRNSPresentation of RXC007 Preclinical Efficacy Data
10th May 20237:00 amRNSNotice of Interim Results
3rd May 20237:00 amRNSRedx to Present at Keystone Symposia
3rd Apr 20237:01 amRNSProposed Business Combination Formally Lapsed
3rd Apr 20237:00 amRNSTermination of Proposed Business Combination
30th Mar 20238:36 amRNSForm 8.5 (EPT/RI) - Redx Pharma plc
27th Mar 20232:06 pmRNSStatement Following Jounce Announcement
27th Mar 20232:00 pmRNSStatement re Merger Agreement
24th Mar 20232:31 pmRNSForm 8.3 - Jounce Therapeutics, Inc
22nd Mar 20232:20 pmRNSForm 8.3 - Jounce Therapeutics, Inc
20th Mar 20233:00 pmRNSForm 8.3 - Jounce Therapeutics, Inc
20th Mar 202310:38 amRNSForm 8.5 (EPT/RI)
16th Mar 20239:48 amRNSForm 8.5 (EPT/RI)
15th Mar 20234:40 pmRNSSecond Price Monitoring Extn
15th Mar 20234:35 pmRNSPrice Monitoring Extension
15th Mar 20232:05 pmRNSSecond Price Monitoring Extn
15th Mar 20232:00 pmRNSPrice Monitoring Extension
15th Mar 202310:50 amRNSStatement re: Jounce Therapeutics Press Release
14th Mar 202311:45 amRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.